WILMINGTON, Del. — AstraZeneca on Monday announced the availability of its Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol in the United States. The drug is indicated for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis or emphysema.
Bevespi Aerosphere was approved by the Food and Drug Administration in April 2016, and the company said it’s the first product approved using its co-suspension technology, which it says allows for consistent delivery of one or more medicines from the same pressurized metered dose inhaler.
“At AstraZeneca, we are committed to following the science to improve the lives of people living with respiratory diseases,” AstraZeneca VP U.S. respiratory Tosh Butt said. “I’m thrilled that Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol is now available in pharmacies across the US.”